Recent Finacing
Recent Raise
Tr1X develops allogeneic engineered Treg and CAR‑Treg therapies, advancing TRX103 into Phase 1 to prevent GvHD post‑mismatched hematopoietic stem cell transplant, with programs for IBD, T1D, and B‑cell autoimmune diseases.
